Immunofusion

ENHANCING
THE
NATURE

Immunofusion LLC is a Belarussian biotechnology company founded in 2018. The company focused on the discovery, development, and commercialization of synthetic DNA products for cancer and infectious diseases immunotherapy. Our company develops a number of innovative drug designs including DNA vaccines, immunocytokines, genetic modifications and CAR-T cell therapy.

prostate cancer vaccine

Prostate cancer is the second most common type of cancer among men and the fourth most common type overall. Surgical treatment, chemotherapy, radiation and hormone therapy are used to treat the metastatic form of prostate cancer, however stage 4 remains an incurable disease. Prostate cancer is a good candidate for immunotherapy for a number of reasons: it is a slowly progressing disease with prolonged periods of treatment without the use of high-dose chemotherapy, which provides sufficient time for the immune response to vaccine to occur. From the immunological point of view, this disease along with melanoma is the best-studied cancer type.

We are developing a vaccine containing the most common tumor-associated antigens such as the Prostate Specific Antigen (PSA), Prostatic Acid Phosphatase (PAP), Prostate Specific Membrane Antigen (PSMA) and New York esophageal squamous cell carcinoma 1 (NY-ESO-1).

COVID-19 VACCINE

The coronavirus COVID-19 pandemic is the biggest global health challenge of 2020 and most likely several years to follow. IMMUNOFUSION has begun developing a DNA vaccine against coronavirus. Our vaccine is designed to create a long-lasting antibody and T-cell response. The vaccine design implements the principle of pan-coronavirus vaccine, which implies an immune response against all beta-coronaviruses, including SARS-1, SARS-CoV-2 and others.

The vaccine is tested in injectable, inhalant and oral forms.

CAR-T THERAPY

We are developing a number of innovative designs to fundamentally improve the 4th generation CAR for treatment of various oncological diseases as well as additional methods of CAR-T cell production.

Pipeline

pipeline

contacts

CEO
Oleg Volkov, MD
immunofusion@gmail.com
+375 29 576 88 56

LEGAL ADDRESS
5-th Cooperativnaya str., 8/4, Vitebsk city, Belarus, 210004 тel/Fax: + 375 0212 352 061

LOCATION (ACTUAL POST ADDRESS)
Office 16, (4th floor), Arena City Center, 28 Pobeditelei ave., Minsk, 220030 Belarus, signed “Immunofusion”

LABORATORY ADDRESS
Belarus, vulica Akademičnaja 28, Minsk, 220072